This week ACS CAN participated in a chemotherapy informational hearing at the State Capitol on the unequal cost cancer patients incur for oral (pill and liquid) versus intravenous (IV) chemotherapies on Idaho’s state-based health care plans. As targeted oral chemotherapy advances, it is apparent that the most effective or, in